Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 2;13(6):e071098.
doi: 10.1136/bmjopen-2022-071098.

Randomised, controlled, open-label pragmatic trial evaluating changes in functional exercise capacity after primary care PU lmonary RE habilitation in patients with long COVID: protocol of the PuRe-COVID trial in Belgium

Affiliations

Randomised, controlled, open-label pragmatic trial evaluating changes in functional exercise capacity after primary care PU lmonary RE habilitation in patients with long COVID: protocol of the PuRe-COVID trial in Belgium

Tess Volckaerts et al. BMJ Open. .

Abstract

Introduction: Long COVID is a prevalent condition with many multisystemic symptoms, such as fatigue, dyspnoea, muscle weakness, anxiety, depression and sleep difficulties, impacting daily life and (social and physical) functioning. Pulmonary rehabilitation (PR) may improve physical status and symptoms of patients with long COVID, yet the evidence is limited. Therefore, this trial aims to study the effect of primary care PR on exercise capacity, symptoms, physical activity and sleep in patients with long COVID.

Methods and analysis: PuRe-COVID is a prospective, pragmatic, open-label, randomised controlled trial. A sample of 134 adult patients with long COVID will be randomised to a 12 week PR programme in primary care, supervised by a physiotherapist or to a control group, following no PR. A 3 month and 6 month follow-up period is foreseen. The primary endpoint will be the change in exercise capacity measured by 6-minute walk distance (6MWD) at 12 weeks, hypothesising a more significant improvement in the PR group. Other parameters, such as pulmonary function tests (including maximal inspiratory pressure/maximal expiratory pressure), patient-reported outcomes (COPD Assessment Test, modified Medical Research Council Dyspnoea Scale, Checklist Individual Strength, post-COVID-19 Functional Status, Nijmegen questionnaire, Hospital Anxiety and Depression Scale, Work Productivity and Activity Impairment Questionnaire and EuroQol-5D-5L), physical activity measured by an activity tracker, hand grip strength and sleep efficiency, are secondary and exploratory outcomes.The recruitment started on 19 April 2022, and 52 patients were included as of 14 December 2022.

Ethics and dissemination: Ethical approval was obtained in Belgium from the relevant institutional review boards on 21 February 2022 (Antwerp University Hospital, approval number 2022-3067) and on 1 April 2022 (Ziekenhuis Oost-Limburg in Genk, approval number Z-2022-01). Findings from this randomised controlled trial will be disseminated in peer-reviewed publications and presentations at international scientific meetings.

Trial registration number: NCT05244044.

Keywords: COVID-19; medical education & training; primary care.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Participant flow chart. This figure gives an overview of used recruitment channels and the flow of a patient participating in the trial. GP, general practitioner; PT, physical therapist; UZA, Antwerp University Hospital; ZOL, Ziekenhuis Oost-Limburg.

References

    1. Ballering AV, van Zon SKR, olde Hartman TC, et al. . Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. The Lancet 2022;400:452–61. 10.1016/S0140-6736(22)01214-4 - DOI - PMC - PubMed
    1. NICE, the Scottish Intercollegiate Guidelines Network (SIGN) and the Royal College of General Practitioners (RCGP) . COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020.
    1. Sivan M, Taylor S. NICE guideline on long Covid. BMJ 2020;371:m4938. 10.1136/bmj.m4938 - DOI - PubMed
    1. Cutler DM. The costs of long COVID. JAMA Health Forum 2022;3:e221809. 10.1001/jamahealthforum.2022.1809 - DOI - PubMed
    1. Zapatero DC, Hanquet G, Van den K. Epidemiology of long COVID: a pragmatic review of the literature. In: COVID 19 – KCE Contributions. 2021.

Publication types

Associated data